Frontiers in Oncology | Cancer Immunity and Immunotherapy

Mini Review

Accepted on 31 Jul 2025

Research Advances in Immune Agonists and Their Nanoparticles for Enhancing the Immunotherapeutic Efficacy of PD-1 Inhibitors in Malignancies

in Cancer Immunity and Immunotherapy

Renjie Xia
Juan Liang
Jianguo Ma
Xiaoyu Du
Liangbin Ma
Xiongxiong Han
Yong Wang
Jianwei Qin
Long Yan

Frontiers in Oncology

doi 10.3389/fonc.2025.1618903

Brief Research Report

Accepted on 31 Jul 2025

Effectiveness and safety of nivolumab and ipilimumab in older adults with renal cell carcinoma: findings from a multicenter observational study in Poland

in Cancer Immunity and Immunotherapy

Artur Drobniak
Łukasz Stokłosa
Aleksandra Grela-Wojewoda
Jacek Calik
Natalia Versuti Viegas
Jolanta Dobrzańska
Agnieszka Roman
Marek Szwiec
Anna Bidas
Daria Tusień-Małecka

Frontiers in Oncology

doi 10.3389/fonc.2025.1617743

110 views

Original Research

Accepted on 29 Jul 2025

Extracellular Matrix-Related Genes-Based Prognostic Signature for Cervical Cancer: Association of LAMA4 Expression with Prognosis and Response to Immunotherapy

in Cancer Immunity and Immunotherapy

Fengchun Gao
Hongyu Shi
Huanhuan Wang
Jin Wang
Dongdong Hao
Yichen Fang

Frontiers in Oncology

doi 10.3389/fonc.2025.1562115

Case Report

Accepted on 29 Jul 2025

Safety and clinical efficacy of immune checkpoint inhibitors in pediatric hepatocellular carcinoma: a case report and review of the literature

in Cancer Immunity and Immunotherapy

Xiaoting Zhong
Xuejiao Wen
Xinping Wang
Jianming Ye
Li Huang
Jing Wang
Jun Chi
Xiaoli Zeng

Frontiers in Oncology

doi 10.3389/fonc.2025.1576892

130 views

Original Research

Accepted on 29 Jul 2025

Peripheral blood TCR repertoire improves early detection across multiple cancer types utilizing cancer predictor

in Cancer Immunity and Immunotherapy

Yinglei Tang
Xinyi Liao
Bo Liao
Dejun Peng
Qingbo Li

Frontiers in Oncology

doi 10.3389/fonc.2025.1625369

175 views

Original Research

Accepted on 28 Jul 2025

Clinical Features and Risk Factors of Immune-Mediated Liver Injury in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

in Cancer Immunity and Immunotherapy

Ling Yang
Chao Zhuo
Chonghuan Li
Yujing Liu
Xinyi Liu
Yibin Huang
Bingbing Wu
Jiawei Su

Frontiers in Oncology

doi 10.3389/fonc.2025.1575376

Original Research

Accepted on 28 Jul 2025

Reporting of immune-related adverse events (irAEs) in US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

in Cancer Immunity and Immunotherapy

Shaili Tapiavala
Chongliang Luo
Mina Shenouda
Vaibhav Patel
Andrew Davis

Frontiers in Oncology

doi 10.3389/fonc.2025.1606599

104 views

Review

Accepted on 28 Jul 2025

CD70 as a Target in Cancer Immunotherapy: advances, challenges, and future directions

in Cancer Immunity and Immunotherapy

Ruchen Wu
Junze Chen
Gang Wang
Lulu Han

Frontiers in Oncology

doi 10.3389/fonc.2025.1609840

116 views

Original Research

Accepted on 25 Jul 2025

Blood memory CD8 T cell phenotypes in lung cancer patients predict immune checkpoint treatment responses

in Cancer Immunity and Immunotherapy

Kanxing Wu
Florian Schmidt
Ke Xin Bok
Yovita Ida Purwanti
Nicholas Tan
Daniel Carbajo
Andreas Wilm
Michael Fehlings
Daniel MacLeod
Alessandra Nardin

Frontiers in Oncology

doi 10.3389/fonc.2025.1629802

153 views

Review

Accepted on 25 Jul 2025

A review of the participation of DDIT4 in the tumor immune microenvironment through inhibiting PI3K-Akt/mTOR pathway

in Cancer Immunity and Immunotherapy

云姝焦
Yang Xiang

Frontiers in Oncology

doi 10.3389/fonc.2025.1595463

119 views

Original Research

Published on 25 Jul 2025

Association between emotional distress and the efficacy of advanced gastric cancer patients undergoing treatment with immune checkpoint inhibitors: a cohort study and propensity score matching study

in Cancer Immunity and Immunotherapy

Ruoxi Tian
Siqi Wang
Zhengzheng Ji
Jiasong Li
Jingjing Zhang
Shasha Zhang
Zhanjun Guo

Frontiers in Oncology

doi 10.3389/fonc.2025.1516643

341 views

Correction

Accepted on 24 Jul 2025

Correction: Enhanced anti‑tumor efficacy of “IL‑15 and CCL19” ‑secreting CAR‑T cells in human glioblastoma orthotopic xenograft model

in Cancer Immunity and Immunotherapy

Wanqiong Chen
Limian Hong
Shaomei Lin
Na Xian
Cailing Yan
Ningning Zhao
Yonglei Xiao
Wanting Liao
Yuxiang Huang
Mingzhu Chen

Frontiers in Oncology

doi 10.3389/fonc.2025.1645247

125 views

Original Research

Published on 24 Jul 2025

Single-cell sequencing combined with machine learning to identify glioma biomarkers and therapeutic targets

in Cancer Immunity and Immunotherapy

Yu Yan
Zhengmin Chu
Qi Zhong
Genghuan Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1629102

566 views

Mini Review

Accepted on 23 Jul 2025

Impact of Sympathetic Nervous System on Immune Evasion in High-Grade Serous Ovarian Cancer: A Review

in Cancer Immunity and Immunotherapy

Ruiyuan Yu
Yumeng Li
Runze Jiang
Chunxiao Dang
Fengting Zhai

Frontiers in Oncology

doi 10.3389/fonc.2025.1644895

185 views

Case Report

Published on 22 Jul 2025

Case Report: Personalized peptide-based immunization in an advanced-stage prostate cancer patient with bone metastasis

in Cancer Immunity and Immunotherapy

Nils Heinrich Thoennissen
Mari Carmen Martos-Contreras
Mehdi Manoochehri
Mauro Nogueira
Franziska Bremm
Jan Dörrie
Jan Christoph
Meik Kunz
Wolfgang Schönharting

Frontiers in Oncology

doi 10.3389/fonc.2025.1596315

435 views

Original Research

Accepted on 21 Jul 2025

High stroma-tumor ratio is associated with immuno-suppressive tumor microenvironment and poor prognosis in bladder cancer

in Cancer Immunity and Immunotherapy

Yiqiang Da
Zirong Lu
Zijian Zhu
Hongrui Tai
Yuan Liu
Yichao Zhu

Frontiers in Oncology

doi 10.3389/fonc.2025.1604609

165 views